Navigation Links
Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
Date:10/11/2007

ZUG, Switzerland, October 11 /PRNewswire/ -- The young Swiss biotech enterprise AMVAC AG has gained reinforcement from Prof. Michel Klein, one of the world's most renowned vaccine specialists. Prof. Klein, who was formerly Vice President of Science & Technology of the Aventis-Pasteur Group, will immediately assume directorship of the scientific sector of vaccine development at AMVAC AG. This distinguished vaccinologist has access to an outstanding network across one of the greatest growth markets and will make a critical contribution in AMVAC AG's product research and development. Along with the vaccine against bacterial vaginosis already approved in Hungary, Klein is focusing on the further development of a vaccine against prostate enlargement, for which the performance of a clinical phase III study has been approved. In addition, AMVAC AG is preparing new projects for indications unnamed until now. Official statements on more new projects in the pharmaceutical industry will be released in the coming weeks.

Melinda Karpati, CEO of AMVAC, AG says, "Being able to win Prof. Michel Klein is a great success for us and affirms not only AMVAC AG's executive? direction, but also the continued recognition that we have come to know on the part of experienced experts in the field of vaccine development. His global network and the tremendous experience that Prof. Michel Klein brings to AMVAC AG will help us develop novel prophylactic and immunotherapeutic products in the pharmaceutical industry. Our new CSO's 40-year career has included numerous scientific publications, distinctions and groundbreaking vaccine developments. He has developed the five-component acellular pertussis vaccine currently on the market, brought vaccines against PIV-3, RSV and flu to phase I/II trials, launched the cancer vaccine program of Aventis-Pasteur and performed more than 40 trials with several prototypes of prophylactic and therapeutic HIV vaccines in collaboration with the NIH, WRAIR, Eurovac and the ANRS. He is the author of more than 350 patents in the fields of vaccinology, immunology, infectious diseases and biotechnology.

About AMVAC AG

AMVAC AG is a young biopharmaceutical company based in Switzerland that is concentrating in the high-yield pharmaceutical industry on an especially high-growth market segment. An average annual growth rate of 13% is forecast until 2010 for the vaccines market, compared with 6% for pharmaceuticals in general. AMVAC products are further characterized by meeting unfulfilled therapy requirements in the fields of urology and gynecology. AMVAC has to date licensed and further developed two advanced immunotherapeutic drugs with gold standard potential. Further products are in the planning stage.

Contact:

AMVAC AG

Ariane Meynert

Metallstrasse 4

6300 Zug

Switzerland

Phone: +41-41-725-32-30

Fax: +41-41-725-32-33

Mobile: +41-79-793-34-19 / +49-172-775-92-12

E-Mail:meynert@amvac.ch


'/>"/>
SOURCE AMVAG AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Safe Internet requires total network security, prof. says
2. Daugherty becomes CTO of Great Lakes BioFuels
3. DataPod becomes BeInSync so you can, too
4. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
5. Historic observatory becomes hot property on Lake Geneva
6. State technology chief endorses IT audit recommendations
7. Fusion 2007: CA chief says IT complexity raises risk
8. Web-Based Learning Developed under new Chief Education Officer
9. UW-Madisons Beebe wins scientific award
10. Researchers say scientific reporting needs more perspective, less hype
11. Wisconsin stands at the center of scientific efforts to avert flu epidemics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... MENLO PARK, Calif. , Feb. 4, 2016 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development and commercialization ... at the 18 th Annual BIO CEO & ... a.m. EST in New York, NY . ... will provide an update on the ongoing clinical trial of ...
(Date:2/4/2016)... Feb. 4, 2016 Sinovac Biotech Ltd. ("Sinovac" ... provider of biopharmaceutical products in China ... board of directors received on February 4, 2016 a ... a consortium comprised of PKU V-Ming ( Shanghai ... Ltd., CICC Qianhai Development ( Shenzhen ) ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, ... with the first pluripotent stem cell-derived islet replacement ... in clinical-stage development, today announced that ViaCyte and ... Companies of Johnson & Johnson, have agreed to ... into ViaCyte.  The agreement provides ViaCyte with an ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
Breaking Biology Technology:
(Date:1/22/2016)... http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced the ... in Retail Sector 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
(Date:1/11/2016)... Jan. 11, 2016  higi, the leading retail ... retail locations, web and mobile, today announced it ... from existing investors. --> ... to further innovate higi,s health platform – its ... portal – including expanding services and programs to ...
Breaking Biology News(10 mins):